Clinical study of Huangjin Shuangshen Granules in treating patients with anxiety and depression after coronary stent implantation

Innovative research and application of the clinical scheme of

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2000003774

Enrollment

Unknown

Registered

2020-08-27

Start date

2020-08-31

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety and depression after coronary stent implantation

Interventions

experimental group:Huangjin Shuangshen Granules

control group:Huangjin Shuangshen Granules Simulant

HJSSJWKLHJSSJWKLMNJ

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) After percutaneous coronary stent implantation and conventional Western medical treatment; 2) TCM syndrome differentiation is the mutual syndrome of stasis, poison and stagnation; 3) 18-75 years old, gender is not limited; 4) Heart function classification <= NYHA II Grade and echocardiographic ejection fraction 45%; 5) Subjects must give informed consent to this trial and sign an informed consent form before the trial.

Exclusion criteria

Exclusion criteria: 1) Stroke (cerebral hemorrhage, subarachnoid hemorrhage, cerebral thrombosis, cerebral embolism and stroke of unknown type) within the past 6 months; 2) Poorly controlled hypertension (>=180/100mmHg) or hypotension (= 2 x upper limit of clinical reference value), other serious primary diseases, tumors or mental diseases that affect life span; 5) Pregnancy, planned pregnancy or lactation Women; 6) Known bleeding tendency or bleeding disease, or uncontrollable coagulation mechanism disorder, or active bleeding and invasive examination and treatment operations within 2 weeks, or history of severe trauma or major surgery within 12 weeks; 7) Those who are participating in other clinical trials; 8) Those who are allergic to the experimental drugs and their constituents; 9) The current or past history of drug abuse or drug use; 10) Suffering from dementia or severe mental disorders that make it unable to understand or express knowledge Those who agree; 11) Those who are drug or alcohol dependent, or other situations where the researcher thinks it is inappropriate to participate in this study.

Design outcomes

Primary

Measure	Time frame
The incidence of major cardiovascular and cerebrovascular adverse events;	—

Secondary

Measure	Time frame
Blood lipids;TCM syndrome score;Seattle Angina Questionnaire, SAQ;Hamilton Depression Scale (HAMD-24);Pittsburgh Sleep Quality Scale;Hamilton Anxiety Scale (HAMA-14);	—

Countries

China

Contacts

Public ContactYao Kuiwu

Guang'anmen Hospital, China Academy of Chinese Medical Sciences

yaokuiwu@126.com+86 18610366611

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026